Sclerostin and Osteoprotegerin Levels Altered in CAH Children, Lacking Pubertal Decline
Background
Children with congenital adrenal hyperplasia (CAH) require lifelong glucocorticoid therapy, which can negatively impact bone metabolism and peak bone mass acquisition. While bone mineral density (BMD) is routinely monitored, the specific molecular mechanisms underlying potential bone health issues in this population, particularly involving key regulators like sclerostin and osteoprotegerin, remain underexplored. Sclerostin, an osteocyte-derived protein, is a potent negative regulator of Wnt signaling and bone formation, while osteoprotegerin acts as a decoy receptor for RANKL, inhibiting osteoclastogenesis and bone resorption. Understanding their roles could reveal new therapeutic targets for preserving skeletal health in CAH.
Study Design
This cross-sectional study investigated serum sclerostin and osteoprotegerin levels in 31 children with CAH (mean age 11.6 ± 3.7 years) who had been taking glucocorticoids for at least 5 years. An age- and gender-matched healthy control group was also included. Researchers assessed serum levels of sclerostin, osteoprotegerin, and standard bone markers using ELISA. Bone mineral density (BMD) was measured via dual-energy X-ray absorptiometry (DEXA). Generalized linear modeling was employed to identify factors influencing sclerostin and osteoprotegerin levels, including cumulative glucocorticoid dose, vitamin D status, pubertal stage, and sex.
Results
In healthy controls, pubertal status was associated with lower serum sclerostin levels, an expected physiological response promoting bone growth. However, pubertal CAH patients did not demonstrate this expected decline in sclerostin levels. Osteoprotegerin levels were significantly higher in CAH patients compared to controls (p < 0.001). Serum 17-hydroxy progesterone exerted a significant negative effect on osteoprotegerin levels and a positive effect on sclerostin levels, suggesting a link to disease control. Notably, cumulative glucocorticoid dose, vitamin D status, pubertal status, and sex had no significant effect on either sclerostin or osteoprotegerin levels in the patient group. Despite these molecular alterations, BMD Z-scores exceeded -1 in 80% of both the patient and control groups.
Pubertal patients with congenital adrenal hyperplasia did not demonstrate the expected decline in sclerostin levels observed in healthy controls, indicating a potential disruption in bone formation regulation during a critical growth phase.
Key Findings
- Pubertal CAH patients did not show the expected decline in serum sclerostin levels seen in healthy pubertal controls.
- Osteoprotegerin levels were significantly higher in CAH patients than in controls (p < 0.001).
- Serum 17-hydroxy progesterone negatively affected osteoprotegerin and positively affected sclerostin levels.
- Cumulative glucocorticoid dose, vitamin D, pubertal status, and sex did not significantly impact sclerostin or osteoprotegerin levels in CAH patients.
- BMD Z-scores were above -1 in 80% of both CAH patients and controls.
Why It Matters
This study highlights that children with congenital adrenal hyperplasia exhibit distinct alterations in sclerostin and osteoprotegerin dynamics, particularly the absence of a crucial pubertal sclerostin decline. These findings suggest that despite seemingly normal BMD Z-scores, CAH patients may have impaired peak bone mass acquisition due to dysregulated bone formation pathways. This could have long-term implications for skeletal health and fracture risk. Future research should explore whether targeting sclerostin or modulating osteoprotegerin could be a viable strategy to optimize bone health in CAH, especially during puberty. The association with 17-hydroxy progesterone also points to the importance of disease control in managing bone health in this population.
sclerostin
osteoprotegerin
congenital-adrenal-hyperplasia
bone-metabolism
glucocorticoids
pediatric